#最小單位貼紙

抗病毒藥品
1. Treatment of HIV-1 infection in patients ≥12 y/o as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA ≤100,000 copies/mL
2. To replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components

#仿單變更2022

Rilpivirine: Non-nucleoside Reverse Transcriptase Inhibitor
Binds to reverse transcriptase and does not require intracellular phosphorylation for antiviral activity
Emtricitabine: Nucleoside Reverse Transcriptase Inhibitor
Cytidine analogue
Tenofovir alafenamide fumarate: Non-nucleotide Reverse Transcriptase Inhibito
analog of adenosine 5'-monophosphate

Concurrent use of carbamazepine, systemic dexamethasone (>1 dose), oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors (PPIs) (eg, dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole), rifampin, rifapentine, and/or St John's wort.

Females who become pregnant while taking this combination may continue if viral suppression is effective and the regimen is well tolerated; however, more frequent monitoring is recommended.
Contraceptive measures should be taken while using the drug.<20221220>

Emtricitabine is present in breast milk; it is not known if rilpivirine or tenofovir alafenamide are present in breast milk.
To prevent HIV transmission to infants,women with HIV should not breastfeed their babies. . <20240223>

Headache, sleep disorder, abnormal dreams, diarrhea, nausea, flatulence, decreased bone mineral density, drowsy/fatigue (影響駕駛、操作機械能力)<20220429>

One tablet once daily, take with a meal
(Do not use in patients with HIV RNA ≥100,000 copies/mL and/or CD4 count ≤200 cells/mm³)

1. Ages <12 years or weight <35 kg: Not recommended
2. Children >12 years and Adolescents weighing >35 kg: One tablet once daily

1. CrCl ≥30 mL/min: No dosage adjustment necessary
2. CrCl <30 mL/min: Use is not recommended
3. ESRD on hemodialysis: One tablet once daily; administer after hemodialysis on dialysis days.
4. Discontinuation should be considered in patients with clinically significant decreased renal function or evidence of proximal tubular disease.<20221220>

1. Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustments necessary
2. Severe impairment (Child-Pugh class C): No dosage adjustments provided in the manufacturer's labeling (has not been studied)